Teachers Retirement System of The State of Kentucky Holds Stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR)

Teachers Retirement System of The State of Kentucky held its position in Acorda Therapeutics, Inc. (NASDAQ:ACOR) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 11,700 shares of the biopharmaceutical company’s stock at the end of the first quarter. Teachers Retirement System of The State of Kentucky’s holdings in Acorda Therapeutics were worth $246,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ACOR. C WorldWide Group Holding A S bought a new position in Acorda Therapeutics during the first quarter valued at $106,000. State of Alaska Department of Revenue boosted its position in Acorda Therapeutics by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 5,120 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 130 shares during the period. Hikari Power Ltd bought a new position in Acorda Therapeutics during the first quarter valued at $210,000. Mason Street Advisors LLC boosted its position in Acorda Therapeutics by 7.7% in the first quarter. Mason Street Advisors LLC now owns 10,852 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 775 shares during the period. Finally, Karp Capital Management Corp bought a new position in Acorda Therapeutics during the first quarter valued at $265,000.

Shares of Acorda Therapeutics, Inc. (ACOR) traded up 1.22% on Friday, reaching $20.70. 89,662 shares of the company traded hands. The company’s market capitalization is $965.45 million. The firm has a 50-day moving average price of $20.74 and a 200 day moving average price of $20.34. Acorda Therapeutics, Inc. has a one year low of $13.60 and a one year high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.16. The business had revenue of $139.40 million during the quarter, compared to analyst estimates of $139.81 million. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. Acorda Therapeutics’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 earnings per share. Equities analysts forecast that Acorda Therapeutics, Inc. will post $1.71 EPS for the current fiscal year.

WARNING: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/11/teachers-retirement-system-of-the-state-of-kentucky-holds-stake-in-acorda-therapeutics-inc-nasdaqacor.html.

Several research analysts have recently weighed in on ACOR shares. BidaskClub cut shares of Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 13th. Stifel Nicolaus reiterated a “buy” rating on shares of Acorda Therapeutics in a report on Friday, July 28th. TheStreet cut shares of Acorda Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, April 24th. Jefferies Group LLC started coverage on shares of Acorda Therapeutics in a report on Monday, July 10th. They issued a “hold” rating and a $22.00 price target for the company. Finally, J P Morgan Chase & Co set a $24.00 price target on shares of Acorda Therapeutics and gave the company a “hold” rating in a report on Tuesday, June 6th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $25.26.

In other news, insider Ron Cohen bought 20,000 shares of the business’s stock in a transaction on Friday, June 16th. The stock was acquired at an average price of $16.95 per share, with a total value of $339,000.00. Following the completion of the purchase, the insider now directly owns 511,648 shares in the company, valued at $8,672,433.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew A. Hindman sold 7,704 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $15.75, for a total value of $121,338.00. Following the completion of the sale, the insider now directly owns 46,123 shares of the company’s stock, valued at approximately $726,437.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,704 shares of company stock valued at $553,638. 7.90% of the stock is owned by insiders.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

What are top analysts saying about Acorda Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acorda Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit